JUL 16, 2020 7:42 AM PDT

Cancer Vaccine Charges Toward the Clinic

WRITTEN BY: Tara Fernandez

Kristen Radford, a professor at Australia’s University of Queensland is leading a scientific research team that's developing the next generation of therapeutic cancer vaccines. Their vaccine, which showed promising results in preclinical trials, has hit a new milestone as the team now plans to test its efficacy in human clinical trials.

According to Radford, this experimental vaccine has immense potential in treating a wide spectrum of malignancies. "We are hoping this vaccine could be used to treat blood cancers, such as myeloid leukemia, non-Hodgkin's lymphoma, multiple myeloma, and pediatric leukemias, plus solid malignancies including breast, lung, renal, ovarian, and pancreatic cancers, and glioblastoma," she said.

The vaccine is a chimera, made up of human antibodies that are genetically fused to a tumor-specific protein called Wilms’ tumor 1, or WT1. The WT1 protein is one of the most studied tumor-associated antigens, meaning that the presence of WT1 on tumors can flag down circulating immune cells to target and destroy the cancerous cells. Due to its high immunogenicity, WT1 is a prime target for therapeutic cancer vaccine development.

Vaccines can train the immune system to recognize and eliminate invading pathogens and malignant cells. There are currently two types of cancer vaccines, ones that either prevent cancer development or vaccines that are applied therapeutically to wipe out residual tumors after therapy and prevent cancer from recurring. Most of the therapeutic vaccines are still in development and not widely available outside of a clinical trial setting.

Radford and colleagues believe that this new cancer vaccine has an edge over other similar treatments in development.

Speaking on these advantages, she commented, "First, it can be produced as an 'off the shelf' clinical-grade formulation, which circumvents the financial and logistical issues associated with patient-specific vaccines."

"Secondly, this prototype vaccine targets the key tumor cells required for the initiation of tumor-specific immune responses, thereby maximizing the potential effectiveness of treatment, while minimizing potential side effects.”

“We are very happy to see our research published in a prestigious journal, and we hope our continued work towards finding a safe and effective cancer vaccine will benefit cancer patients in the future,” added Radford, whose study has recently been published in the highly ranked journal, Clinical and Translational Immunology.

 

 

Sources: Clinical and Translational Immunology, Translational Research Institute.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
SEP 21, 2020
Immunology
The Perfect Storm: Wildfires, Flu and COVID-19
SEP 21, 2020
The Perfect Storm: Wildfires, Flu and COVID-19
Over 85 massive wildfires have swept through the West Coast, devastating communities in Washington, Oregon, and Californ ...
OCT 20, 2020
Immunology
The Immune Pause Button Slowing MS Progression
OCT 20, 2020
The Immune Pause Button Slowing MS Progression
  Scientists have a new theory about the genetics behind the progressive, debilitating effects of multiple sclerosi ...
NOV 16, 2020
Immunology
Measles Is Back and COVID Isn't Helping
NOV 16, 2020
Measles Is Back and COVID Isn't Helping
Measles is a highly contagious and airborne viral disease. There is no treatment besides supportive care once a person b ...
NOV 17, 2020
Drug Discovery & Development
Antibiotics Before Age 2 Linked to Childhood Health Conditions
NOV 17, 2020
Antibiotics Before Age 2 Linked to Childhood Health Conditions
Researchers from Mayo Clinic have found a link between children aged two and under taking antibiotics and an increased r ...
DEC 28, 2020
Genetics & Genomics
Mapping Networks of Gene Expression in Cells
DEC 28, 2020
Mapping Networks of Gene Expression in Cells
Every cell contains our whole genome, but not all genes are turned on all the time; gene expression has to be very caref ...
JAN 05, 2021
Immunology
Immune Imbalances Dictate COVID Symptom Severity
JAN 05, 2021
Immune Imbalances Dictate COVID Symptom Severity
COVID symptoms. “As it is often the case for pathogenic infections, the host immune system is a key player in vira ...
Loading Comments...